
Clinical Data With Foscarbidopa/Foslevodopa CSCI in Parkinson Disease
Video content above is prompted by the following: Summary of Phase 3 Clinical Trials for Continuous Subcutaneous Foscarbidopa/Foslevodopa 12-Week Randomized, Double-Blind Trial Efficacy Significant reduction in OFF time compared to placebo (primary end …